JAAD Game Changers: Dupilumab shows long-term safety and efficacy in patients with moderate-to-severe atopic dermatitis enrolled in a phase 3 open-label extension study

被引：0
|
作者：
Wohltmann, Wendi E. [1 ]
机构：
[1] San Antonio Mil Med Ctr, Dermatol & Pathol, 1100 Wilford Hall Loop, Jbsa Lackland, TX 78236 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 91卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：613 / 613
页数：1
相关论文
共 50 条
  • [31] Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
    Valenzuela, F.
    Korman, N. J.
    Bissonnette, R.
    Bakos, N.
    Tsai, T. -F.
    Harper, M. K.
    Ports, W. C.
    Tan, H.
    Tallman, A.
    Valdez, H.
    Gardner, A. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 853 - 862
  • [32] LONG-TERM EFFICACY AND SAFETY OF DUPILUMAB IN A PHASE 3 OPEN-LABEL EXTENSION TRIAL (LIBERTY AD PED-OLE) IN PATIENTS AGED ≥ 6 TO<12 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Cork, Michael J.
    Thaci, Diamant
    Eichenfield, Lawrence F.
    Arkwright, Peter D.
    Chen, Zhen
    Prescilla, Randy
    Delevry, Dimittri
    O'Malley, John T.
    Bansal, Ashish
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 60 - 60
  • [33] An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Thaci, D.
    Davis, J. D.
    Zhang, Q.
    Akinlade, B.
    Graham, N. M. H.
    Pirozzi, G.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 155 - 155
  • [34] Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years
    Wollenberg, Andreas
    Soong, Weily
    Goooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB106 - AB106
  • [35] Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial
    Wollenberg, Andreas
    Beck, Lisa
    Deleuran, Mette Sondergaard
    Blauvelt, Andrew
    Thyssen, Jacob
    de Bruin-Weller, Marjolein
    Chen, Zhen
    Khokhar, Faisal
    Rodriguez-Marco, Ainara
    Levit, Noah
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB10 - AB10
  • [36] Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Deleuran, Mette
    Blauvelt, Andrew
    Bissonnette, Robert
    de Bruin-Weller, Marjolein
    Hide, Michihiro
    Sher, Lawrence
    Hussain, Iftikhar
    Chen, Zhen
    Khokhar, Faisal A.
    Beazley, Bethany
    Ruddy, Marcella
    Patel, Naimish
    Graham, Neil M. H.
    Ardeleanu, Marius
    Shumel, Brad
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (04) : 567 - 577
  • [37] Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Lisa A. Beck
    Diamant Thaçi
    Mette Deleuran
    Andrew Blauvelt
    Robert Bissonnette
    Marjolein de Bruin-Weller
    Michihiro Hide
    Lawrence Sher
    Iftikhar Hussain
    Zhen Chen
    Faisal A. Khokhar
    Bethany Beazley
    Marcella Ruddy
    Naimish Patel
    Neil M. H. Graham
    Marius Ardeleanu
    Brad Shumel
    American Journal of Clinical Dermatology, 2020, 21 : 567 - 577
  • [38] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Paller, Amy S.
    Flohr, Carsten
    Eichenfield, Lawrence F. F.
    Irvine, Alan D. D.
    Weisman, Jamie
    Soung, Jennifer
    Correia, Ana Pinto
    Natalie, Chitra R. R.
    Capriles, Claudia Rodriguez
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Tubau, Clara Armengol
    Laquer, Vivian
    Weidinger, Stephan
    DERMATOLOGY AND THERAPY, 2023, 13 (07) : 1517 - 1534
  • [39] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Amy S. Paller
    Carsten Flohr
    Lawrence F. Eichenfield
    Alan D. Irvine
    Jamie Weisman
    Jennifer Soung
    Ana Pinto Correia
    Chitra R. Natalie
    Claudia Rodriguez Capriles
    Evangeline Pierce
    Sarah Reifeis
    Renata Gontijo Lima
    Clara Armengol Tubau
    Vivian Laquer
    Stephan Weidinger
    Dermatology and Therapy, 2023, 13 (7) : 1517 - 1534
  • [40] Long-term efficacy and safety data for dupilumab in a phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with moderate-to-severe atopic dermatitis (AD)
    Cork, M. J.
    Thaci, D.
    Eichenfield, L.
    Arkwright, P. D.
    Bastian, M.
    Chen, Z.
    Delevry, D.
    O'Malley, J. T.
    Bansal, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 14 - 14
12345